Lenacapavir, a drug administered twice a year to prevent HIV infection, is being hailed as one of the most important advances in HIV prevention in the past decade. Its promise is drawing attention to the possibility of a new approach to preventing HIV infection.
But the drug’s availability is not equal worldwide. Reports published from the United States highlight a gap between lenacapavir’s potential and the access people have to it in different parts of the world.
Promise and access challenges
The drug’s effectiveness and twice-yearly schedule have made it a significant development in HIV prevention. However, its potential can only be fully realized if access extends beyond the places where it is currently available.
The reports underscore a broader challenge: an important medical advance does not automatically become accessible to people everywhere. For lenacapavir, the gap between its promise and global availability remains a key concern.
